glp-1 medications approved for type 2 diabetes 2025 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with GLP-1 Pipeline Update: November 2025

Advanced GLP-1 Science: Genetic Pathways and Personalized Response Not all people respond identically to GLP-1 therapy because genetic variation affects how your body processes these medications and regulates appetite signals

Infections are rare, but possible A very small risk of infection is possible when taking Lactobacillus (about one in one million people experience this) or when taking yeast-based probiotics (about one in 5.6 million people experience this)

Stakeholders have acknowledged a need for highly characterized peptide-related impurities with known sequences to be used in method development. The widespread use of GLP-1s is unlikely to slow down anytime soon

DNA purification was carried out using SDSproteinase K digestion, phenol/chloroform extraction and ethanol precipitation

Swiss Medical Weekly Young Investigator's Award 2003: Clustering of Cardiovascular Risk Factors Mimicking the Human Metabolic Syndrome X in eNOS Null Mice